Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017


Posted on: 01 Nov 17

SYDNEY, Australia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical Officer, gave an oral presentation at the World Immunotherapy Congress 2017 in Basel, Switzerland at 5.50pm CEST on October 31, 2017.

The presentation included the following information and data:

  • Overview of Lymphocyte Activation Gene-3 (LAG-3) and its structural relationship to the other MHC class II ligand, CD4;
  • Therapeutic potential of engaging (in cancer) or suppressing (in auto-immune diseases) the human immune response by modulating either LAG-3 or its ligand MHC class II;
  • Overview of the unique structure of Prima’s lead product candidate, eftilagimod alpha (LAG-3Ig or IMP321), as a MHC class II agonist and antigen presenting cell activator; and
  • Review of Prima’s ongoing oncology-focused clinical trials of eftilagimod alpha (AIPAC, TACTI-mel and INSIGHT) including:
    • Immune monitoring data from the run-in phase of the AIPAC clinical trial showing robust infiltration of T cells  around tumor noduleswith some  T cells infiltrating the nodules following 13 eftilagimod alpha s.c. injections in a metastatic breast cancer patient treated with paclitaxel weekly; and
    • Three patients have been recruited for Stratum A (intratumoral (i.t.)) and Stratum B (intraperitoneal (i.p.)) of the INSIGHT clinical trial.

The TACTI-mel Phase 1 clinical trial, being undertaken in Australia, is investigating the use of eftilagimod alpha in combination with pembrolizumab (KEYTRUDA) in metastatic melanoma patients. The patients eligible to participate in the TACTI-mel Phase 1 clinical trial are those that have either had no response or a suboptimal response to KEYTRUDA monotherapy as a first-line of treatment.

New data in relation to the first and second patient cohort of TACTI-mel will be presented at the Society for Immunotherapy of Cancer (SITC) 2017 meeting on 10-12 November, as previously announced.

A copy of  Dr Triebel’s presentation slides presented at the World Immunotherapy Congress 2017 is available on Prima’s website in the Presentations section of the Investors tab at http://primabiomed.com.au/investor/presentations.php

Prima BioMed 
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.

For further information please contact:

U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Prima Biomed
+1 (917) 860-9404; jay.campbell@primabiomed.com.au

Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com

Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com

 

GlobeNewswire
globenewswire.com

Last updated on: 01/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.